Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial
Thiery-Vuillemin, A. Saad, F. Armstrong, A. J. Oya, M. Vianna, K. C. M. Ozguroglu, M. Gedye, C. Buchschacher, G. L. Lee, J. Y. Emmenegger, U.
Thiery-Vuillemin, A.
Saad, F.
Armstrong, A. J.
Oya, M.
Vianna, K. C. M.
Ozguroglu, M.
Gedye, C.
Buchschacher, G. L.
Lee, J. Y.
Emmenegger, U.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Thiery-Vuillemin A, Saad F, Armstrong AJ, Oya M, Vianna KCM, Ozguroglu M, et al. Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301435.